Cabozantinib versus other TKIs after CPI treatment in the real-world management of patients with metastatic renal cell carcinoma (mRCC).

被引:7
作者
Marteau, Florence [1 ]
Harrow, Brooke [2 ]
McCarthy, Christine [3 ]
Wallace, Joel [4 ]
Monnette, Alisha [5 ]
Wang Yunfei [6 ]
Doshi, Gurjyot K. [7 ]
机构
[1] IPSEN Pharma SAS, Boulogne, France
[2] Ipsen Inc, Cambridge, MA USA
[3] Ipsen, Boulogne, Ile De France, France
[4] Exelixis, Alameda, CA USA
[5] McKesson, The Woodlands, TX USA
[6] US Oncol Res, McKesson Specialty Hlth, The Woodlands, TX USA
[7] US Oncol Network, McKesson Specialty Hlth, Houston, TX USA
关键词
D O I
10.1200/JCO.2021.39.6_suppl.293
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
293
引用
收藏
页数:2
相关论文
empty
未找到相关数据